PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Health

New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients

An experimental mRNA vaccine targeting KRAS mutations triggered immune responses in 99% of pancreatic cancer patients in recent Phase 2 study results.

14sources
14articles
13velocity
+368%since first seen
18d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

A new experimental vaccine targeting rogue genes linked to 90 percent of pancreatic cancers has demonstrated the ability to trigger immune responses in 99 percent of patients. According to coverage from Oncodaily and ScienceAlert, Cosimo Commisso reported that this personalized KRAS vaccine generated these significant immune responses. The vaccine utilizes mRNA technology to harness the power of the immune system. While the response rate was high, Inkorr reports that the vaccine triggered strong T-cell responses in nearly all patients but failed to delay relapse. The treatment specifically targets KRAS mutations, which are common drivers in the development of pancreatic tumors.

Multiple outlets are tracking the development and presentation of this data. GlobeNewswire and Yahoo Finance UK report that Elicio Therapeutics is scheduled to present results from the Phase 2 AMPLIFY-7P trial at the SITC 2026 Annual Meeting. Investing.com further confirms that Elicio will present KRAS vaccine data at this cancer conference. Additionally, Health and Me and IFLScience have emphasized the vaccine's ability to target the specific genetic mutations linked to the vast majority of these cancer cases, while Medical Xpress notes the investigational nature of the study regarding KRAS mutations.

Contextual reports from Nature and AllSci provide insight into the broader scientific landscape of these treatments. Nature describes the design of a tumor landscape-modifying vaccine that utilizes a unique TLR2/6 agonist for refractory pancreatic cancer. Meanwhile, a team from Yonsei has shown that a dual-antigen KRAS/WNT5a vaccine can enhance pancreatic cancer immunotherapy. These developments are part of a wider trend in mRNA vaccine application, as highlighted by NPR, which is exploring what the latest advancements in mRNA technology mean for the future of cancer treatment and personalized medicine.

Future developments center on the official presentation of the AMPLIFY-7P Phase 2 results at the upcoming SITC 2026 Annual Meeting. Observers and medical professionals will be looking for more detailed data from Elicio Therapeutics to understand why the strong T-cell responses reported by Inkorr did not translate into a delay in patient relapse. Further research into dual-antigen vaccines, such as the KRAS/WNT5a approach mentioned by AllSci, may also provide a path forward for enhancing the efficacy of these immunotherapies in treating refractory pancreatic cancer cases.

Synthesized by PULSE from the headlines below under a strict no-invention contract. Updated 13d ago.

Quick answers

What percentage of patients responded to the vaccine?

The vaccine sparked immune responses in 99% of patients.

Which company is presenting the Phase 2 AMPLIFY-7P results?

Elicio Therapeutics is presenting the results at the SITC 2026 Annual Meeting.

Did the vaccine prevent cancer relapse?

According to Inkorr, while it triggered strong T-cell responses, it failed to delay relapse.

Coverage (14)

Topics

Related trends

\n \n \n \n \n \n \n